Literature DB >> 22546619

Epidemiology and clinical characteristics of parainfluenza virus 3 outbreak in a Haemato-oncology unit.

Heli Harvala1, Eleanor Gaunt, Chloe McIntyre, Huw Roddie, Sharon Labonte, Evonne Curran, Richard Othieno, Peter Simmonds, John Bremner.   

Abstract

OBJECTIVES: We describe molecular investigations of a large hospital outbreak of parainfluenza virus type 3 (PIV3), in which 32 patients became infected. We outline infection control measures that successfully limited further spread of PIV3 in a Haemato-oncology unit.
METHODS: Clinical retrospective review of infected haemato-oncology patients was undertaken. PIV3 haemagglutinin sequences from each case (n = 32) and local epidemiologically unlinked controls (n = 53) were compared to identify potential linkage.
RESULTS: PIV3-infected patients presented with upper (n = 18) and lower (n = 11) respiratory tract infections, 3 showed pyrexia only and one was asymptomatic. All symptomatic patients received antibiotics; bacterial co-infection was confirmed in eleven patients. PIV3 infections were associated with lower mortality than documented previously; three of the PIV3-infected patients died (3/32; 9%). All deaths were associated with relapsed malignancies, and PIV3 was not believed to be the primary cause of death in any of these patients. Sequences from 27 cases clustered closely together, consistent with nosocomial infections from PIV3 circulating within the ward. Factors favouring transmission were high patient turnaround between the day treatment unit and in-patient ward, and limited isolation facilities for immunocompromised and infected patients, especially within the day treatment unit. New infections reduced to baseline levels three days after enhanced infection control interventions were introduced.
CONCLUSIONS: Molecular epidemiological analysis provided evidence for nosocomial transmission of PIV3 infection that facilitated effective implementation of infection control measures. These were instrumental in restricting further spread of the virus among high-risk patients.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22546619     DOI: 10.1016/j.jinf.2012.04.011

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses.

Authors:  Shringkhala Bajimaya; Tsuyoshi Hayashi; Tünde Frankl; Peter Bryk; Brian Ward; Toru Takimoto
Journal:  Virology       Date:  2016-12-02       Impact factor: 3.616

Review 2.  Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation.

Authors:  Erik Vakil; Scott E Evans
Journal:  Clin Chest Med       Date:  2016-12-16       Impact factor: 2.878

3.  Outbreak of Human Parainfluenza Virus Type 1 in a Kindergarten from China, 2018.

Authors:  Hong-Jun Li; Juan Du; Yan-Na Yang; Yan Cui; Lu Xi; Shuai Wang; Ya-Qiong Liu; Guo-Feng Zhang; Fuqiang Cui; Qing-Bin Lu
Journal:  J Pediatr Infect Dis       Date:  2019-09-03       Impact factor: 0.293

Review 4.  Update on infection control practices in cancer hospitals.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly
Journal:  CA Cancer J Clin       Date:  2018-07-09       Impact factor: 508.702

Review 5.  Parainfluenza Virus Infection.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

Review 6.  Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.

Authors:  Marie von Lilienfeld-Toal; Annemarie Berger; Maximilian Christopeit; Marcus Hentrich; Claus Peter Heussel; Jana Kalkreuth; Michael Klein; Matthias Kochanek; Olaf Penack; Elke Hauf; Christina Rieger; Gerda Silling; Maria Vehreschild; Thomas Weber; Hans-Heinrich Wolf; Nicola Lehners; Enrico Schalk; Karin Mayer
Journal:  Eur J Cancer       Date:  2016-09-25       Impact factor: 9.162

Review 7.  Spatial and temporal analyses to investigate infectious disease transmission within healthcare settings.

Authors:  G S Davis; N Sevdalis; L N Drumright
Journal:  J Hosp Infect       Date:  2014-02-26       Impact factor: 3.926

8.  Molecular epidemiology and environmental contamination during an outbreak of parainfluenza virus 3 in a haematology ward.

Authors:  T Kim; C E Jin; H Sung; B Koo; J Park; S-M Kim; J Y Kim; Y P Chong; S-O Lee; S-H Choi; Y S Kim; J H Woo; J-H Lee; J-H Lee; K-H Lee; Y Shin; S-H Kim
Journal:  J Hosp Infect       Date:  2017-09-08       Impact factor: 3.926

9.  A molecular epidemiological study of human parainfluenza virus type 3 at a tertiary university hospital during 2013-2015 in Catalonia, Spain.

Authors:  Cristina Godoy; Paula Peremiquel-Trillas; Cristina Andrés; Laura Gimferrer; Sonia María Uriona; María Gema Codina; Lluis Armadans; María Del Carmen Martín; Francisco Fuentes; Juliana Esperalba; Magda Campins; Tomàs Pumarola; Andrés Antón
Journal:  Diagn Microbiol Infect Dis       Date:  2016-07-27       Impact factor: 2.803

10.  Sources of viral respiratory infections in Canadian acute care hospital healthcare personnel.

Authors:  S Buckrell; B L Coleman; S A McNeil; K Katz; M P Muller; A Simor; M Loeb; J Powis; S P Kuster; J M Di Bella; K K L Coleman; S J Drews; P Kohler; A McGeer
Journal:  J Hosp Infect       Date:  2020-01-16       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.